This inventor holds 2 USPTO granted patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Himari Yamazaki: Innovator in Antisense Oligonucleotide Technology
Introduction
Himari Yamazaki is a notable inventor based in Fujisawa, Japan. He has made significant contributions to the field of molecular biology, particularly in the development of antisense oligonucleotides. His work focuses on innovative methods for splicing modulation, which has implications for treating various diseases.
Latest Patents
Himari Yamazaki holds a patent for "Compositions and methods for splicing modulation of UNC13A." This patent describes antisense oligonucleotides designed to inhibit the inclusion of a cryptic exon into the mature mRNA of UNC13A. The patent also includes pharmaceutical compositions that utilize these oligonucleotides for treating UNC13A-associated diseases or conditions related to TDP-43 dysfunction.
Career Highlights
Yamazaki is currently associated with Takeda Pharmaceutical Company Limited, where he continues to advance his research and development efforts. His innovative approach to splicing modulation has positioned him as a key figure in the pharmaceutical industry.
Collaborations
One of his notable collaborators is Masahiro Nogami. Together, they work on projects that aim to enhance the understanding and treatment of diseases linked to UNC13A and TDP-43.
Conclusion
Himari Yamazaki's contributions to the field of antisense oligonucleotide technology are paving the way for new therapeutic strategies. His innovative work continues to impact the medical community positively.